Alto Neuroscience Inc:概念验证研究中,Alto-101未达到主要终点的统计学显著性

美股速递
Apr 02

在一项概念验证研究中,Alto Neuroscience Inc (ANRO) 宣布,其候选药物Alto-101未能达到研究预设的主要终点的统计学显著性。这一结果意味着,在该研究的主要评估指标上,Alto-101与对照组相比,未显示出具有统计学意义的差异。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10